AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
therapies for inherited retinal diseases (IRDs) focused on large gene delivery via its two proprietary Adeno-Associated Viral (AAV) vector platforms, today announced the appointment of Philip Lao as Senior Vice President of Business Development. Mr. Lao joins the Company's leadership team and will report to Dr. Natalia Misciattelli, Chief Executive Officer. “Philip brings extensive genetic medicine and ophthalmology experience, and his track record of creating value through strategic partnerships will significantly strengthen our business development capabilities at this crucial time for AAVantgarde,” said Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde . “Philip's proven track record will help drive the company's future strategic growth. We are pleased to welcome him to AAVantgarde.” “I am excited to join AAVantgarde and help accelerate the company's progress by expanding strategic partnership and commercial opportunities for our novel pipeline of retinal therape
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE-IgAN Study [Yahoo! Finance]Yahoo! Finance
- The Vanguard ETF Up About 28% in the Past Year That Almost Nobody Outside of Income Investors Knows [Yahoo! Finance]Yahoo! Finance
- AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [TheStreet.com]TheStreet.com
- Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website